NasdaqCM - Delayed Quote USD

Instil Bio, Inc. (TIL)

10.41 -0.24 (-2.25%)
At close: April 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Bronson Crouch Chairman & CEO 672.37k -- 1973
Dr. Sandeep Laumas M.D. CFO & Chief Business Officer 489.14k -- 1969
Dr. Mark E. Dudley Ph.D. Chief Scientific Officer -- -- --
Dr. Robert Hawkins MBBS, Ph.D. Head of Research & Development 218.72k -- --

Instil Bio, Inc.

3963 Maple Avenue
Suite 350
Dallas, TX 75219
United States
972 499 3350 https://instilbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
49

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Corporate Governance

Instil Bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Instil Bio, Inc. Earnings Call

Related Tickers

ASMB Assembly Biosciences, Inc.
13.33
+2.85%
 
NXTC NextCure, Inc.
1.5700
+3.97%
 
CTMX CytomX Therapeutics, Inc.
1.7300
-1.70%
 
GLPG.AS Galapagos NV
27.06
-1.17%
 
AVIR Atea Pharmaceuticals, Inc.
3.7000
-0.27%
 
SPRO Spero Therapeutics, Inc.
1.4700
-2.00%
 
TBPH Theravance Biopharma, Inc.
9.20
-3.36%
 
ACHL Achilles Therapeutics plc
0.8000
-2.91%
 
CLRB Cellectar Biosciences, Inc.
3.0400
-5.30%
 
EIGR Eiger BioPharmaceuticals, Inc.
1.7250
0.00%